The novel roles of stromal fibroblasts in metronomic chemotherapy: Focusing on cancer stemness and immunity

研究成果: 雜誌貢獻回顧型文獻

摘要

Metronomic chemotherapy involves the administration of cytotoxic chemotherapy at reduced doses administered at regular and frequent intervals. Low-dose metronomic (LDM) chemotherapy represents an alternative to standard maximum tolerated dose (MTD) chemotherapy as it is less toxic and offers additional beneficial biological effects; such effects include inhibition of tumor neovascularization and reduced recruitment of immune-suppressive cells. In desmoplastic cancers such as breast and pancreatic cancers, carcinoma-associated fibroblasts (CAFs) in the tumor stroma constitute an important cellular target of systemic chemotherapy, and the treatment-modulated CAFs may deleteriously influence treatment efficacy. Herein, we reviewed the novel roles of CAFs in metronomic chemotherapy in desmoplastic cancers. We discuss the differential effects of MTD- and LDM-chemotherapy on the heterotypic interactions among CAFs and cells in the other cancer compartments, emphasizing the roles of cancer stem cells and myeloid-derived suppressor cells. The novel mechanistic roles of CAFs in cancer therapy provide an additional rationale for the clinical development of LDM chemotherapy.
原文英語
頁(從 - 到)123-126
頁數4
期刊台灣癌症醫學雜誌
4
發行號4
DOIs
出版狀態已發佈 - 2017

Keywords

  • Carcinoma-associated fibroblasts
  • Metronomic chemotherapy
  • Cancer stemness
  • Myeloid-derived suppressor cells

指紋 深入研究「The novel roles of stromal fibroblasts in metronomic chemotherapy: Focusing on cancer stemness and immunity」主題。共同形成了獨特的指紋。

  • 引用此